[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550799":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":36,"locations":42,"responsibleParty":124,"collaborators":35,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":35,"eligibilityCriteria":132,"healthyVolunteers":128,"sex":133,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":35,"studyType":139,"phases":140,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":45,"whyStopped":35,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},{"fullName":5,"class":6},"Verve Therapeutics, Inc.","INDUSTRY",[8,14,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Single Ascending Dose Escalation","EXPERIMENTAL","Participants will receive a single dose of VERVE-201.",[13],"Drug: VERVE-201",{"label":15,"type":10,"description":11,"interventionNames":16},"Cohort 2: Single Ascending Dose Escalation",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Cohort 3: Single Ascending Dose Escalation",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Cohort 4: Single Ascending Dose Escalation",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Cohort 5: Single Ascending Dose Escalation",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Cohort 6: Single Ascending Dose Escalation",[13],[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","VERVE-201","Intravenous (IV) infusion",[9,15,18,21,24,27],null,[37],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},"Clinical Development","CONTACT","781-970-6833","verve201clinicaltrials@lists.lilly.com",[43,55,62,71,78,85,94,101,110,117],{"facility":44,"status":45,"city":46,"state":35,"zip":35,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":35},"Clinical Study Center","RECRUITING","Adelaide","Australia","AU",{"type":50,"coordinates":51},"Point",[52,53],138.59863,-34.92866,{"lat":53,"lon":52},{"facility":44,"status":45,"city":56,"state":35,"zip":35,"country":47,"countryCode":48,"cosmosGeoPoint":57,"geoPoint":61,"contacts":35},"Melbourne",{"type":50,"coordinates":58},[59,60],144.96332,-37.814,{"lat":60,"lon":59},{"facility":44,"status":45,"city":63,"state":35,"zip":35,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":35},"Chicoutimi","Canada","CA",{"type":50,"coordinates":67},[68,69],-71.06369,48.41963,{"lat":69,"lon":68},{"facility":44,"status":45,"city":72,"state":35,"zip":35,"country":64,"countryCode":65,"cosmosGeoPoint":73,"geoPoint":77,"contacts":35},"Montreal",{"type":50,"coordinates":74},[75,76],-73.58781,45.50884,{"lat":76,"lon":75},{"facility":44,"status":45,"city":79,"state":35,"zip":35,"country":64,"countryCode":65,"cosmosGeoPoint":80,"geoPoint":84,"contacts":35},"Toronto",{"type":50,"coordinates":81},[82,83],-79.39864,43.70643,{"lat":83,"lon":82},{"facility":44,"status":45,"city":86,"state":35,"zip":35,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":35},"Cape Town","South Africa","ZA",{"type":50,"coordinates":90},[91,92],18.42322,-33.92584,{"lat":92,"lon":91},{"facility":44,"status":45,"city":95,"state":35,"zip":35,"country":87,"countryCode":88,"cosmosGeoPoint":96,"geoPoint":100,"contacts":35},"Johannesburg",{"type":50,"coordinates":97},[98,99],28.04363,-26.20227,{"lat":99,"lon":98},{"facility":44,"status":45,"city":102,"state":35,"zip":35,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":35},"Liverpool","United Kingdom","UK",{"type":50,"coordinates":106},[107,108],-2.97794,53.41058,{"lat":108,"lon":107},{"facility":44,"status":45,"city":111,"state":35,"zip":35,"country":103,"countryCode":104,"cosmosGeoPoint":112,"geoPoint":116,"contacts":35},"London",{"type":50,"coordinates":113},[114,115],-0.12574,51.50853,{"lat":115,"lon":114},{"facility":44,"status":45,"city":118,"state":35,"zip":35,"country":103,"countryCode":104,"cosmosGeoPoint":119,"geoPoint":123,"contacts":35},"Manchester",{"type":50,"coordinates":120},[121,122],-2.23743,53.48095,{"lat":122,"lon":121},{"type":125,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100550799","phase-1-phase-1b-study-of-verve-201-in-patients-with-refractory-hyperlipidemia-100550799",false,"NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia","A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia","Inclusion Criteria:\n\n* Refractory hypercholesterolemia\n* Refractory hypertriglyceridemia\n\nExclusion Criteria:\n\n* Active or history of chronic liver disease\n* Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":137,"type":138},36,"ESTIMATED","INTERVENTIONAL",[141],"PHASE1","VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.\n\nVERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.",[144,145,146],"Hypercholesterolemia","Hypertriglyceridemia","Refractory Hyperlipidemia",[32,148,149,150,151,152,153,146,154],"Gene Editing","Base Editing","Refractory Hypercholesterolemia","ANGPTL3","ASCVD","Refractory Hypertriglyceridemia","Familial Hypercholesterolemia","2026-04-22",{"date":157,"type":158},"2026-04-28","ACTUAL",{"date":160,"type":158},"2024-10-30",{"date":162,"type":138},"2027-12",{"name":5,"class":6},10]